378 related articles for article (PubMed ID: 32794259)
1. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.
Loomba R; Ling L; Dinh DM; DePaoli AM; Lieu HD; Harrison SA; Sanyal AJ
Hepatology; 2021 Jan; 73(1):126-143. PubMed ID: 32794259
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
3. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
5. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
[TBL] [Abstract][Full Text] [Related]
6. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
7. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
9. Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice.
He B; Jiang J; Shi Z; Wu L; Yan J; Chen Z; Luo M; Cui D; Xu S; Yan M; Zhang S; Chen Z
Biomed Pharmacother; 2021 Mar; 135():111183. PubMed ID: 33401222
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Marey MM; Belal M; Awad AA; Rabea EM; Hassan MA; Abbas AW; Nashwan AJ
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102357. PubMed ID: 38688423
[TBL] [Abstract][Full Text] [Related]
11. A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis.
Li H; Wang M; Chen P; Zhu M; Chen L
Biomed Pharmacother; 2024 May; 174():116617. PubMed ID: 38643542
[TBL] [Abstract][Full Text] [Related]
12. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH).
Roberts SK; Majeed A
Expert Opin Ther Targets; 2021 Oct; 25(10):889-895. PubMed ID: 34727818
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
14. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
[TBL] [Abstract][Full Text] [Related]
15. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
[TBL] [Abstract][Full Text] [Related]
16. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
17. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
18. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice.
Li Q; Li M; Li F; Zhou W; Dang Y; Zhang L; Ji G
J Ethnopharmacol; 2020 Aug; 258():112896. PubMed ID: 32325178
[TBL] [Abstract][Full Text] [Related]
19.
Liu L; Deng L; Wei W; Li C; Lu Y; Bai J; Li L; Zhang H; Jin N; Li C; Zhao C
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762300
[TBL] [Abstract][Full Text] [Related]
20. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Carr RM; Li Y; Chau L; Friedman ES; Lee JJ; Adorini L; Erickson M; Zaru L; Shringarpure R; MacConell L; Bittinger K; Li H; Wu GD
Hepatology; 2023 Dec; 78(6):1843-1857. PubMed ID: 37222264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
